Abstract
B‐cell non‐Hodgkin's lymphoma (B‐NHL) is the most frequent malignant lymphoid neoplasm, which has a high degree of relapse and chemoresistance. Thus, strategies to improve currently used therapies are needed. In this context, a new CXCR4‐targeted delivery system is described using mesoporous silica nanoparticles (MSNs) that are loaded with doxorubicin and capped with a derivative of the T22 peptide (P). This design makes full use of the great affinity of the T22 peptide to CXCR4 receptor, which is overexpressed in lymphoma cells. The peptide is able to guide the gated nanoparticle to B‐NHL cells to facilitate MSNs uptake via the CXCR4 receptor. The endocyted P‐capped MSNs are also opened by endosomal proteolytic enzymes to allow intracellular doxorubicin delivery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
